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We report the epidemiological impact of carbapenemases-producing45
Enterobacteriaceae (CPE) in Spain in 2012. Of the 237 carbapenemases detected 16346
were OXA-48 group, 60 VIM-1, 8 KPC-2, 5 IMP group, and one NDM-1. Inter-hospital47
spread of carbapenemase-producing K. pneumoniae was due to a limited number of48
MLST and carbapenemases types including ST15/VIM-1, ST11/OXA-48, ST405/OXA-49
48, ST101/KPC-2 and ST11/VIM-1. The number of CPE in Spain has increased sharply50







In recent years, Enterobacteriaceae isolates, mainly Klebsiella pneumoniae,57
have increased their potential to become extensively-drug resistant by acquiring58
resistance to carbapenems (1-3), mainly due to the production of carbapenemases.59
In general, carbapenemases hydrolyze all β-lactam antibiotics (1-3). The most 60
clinically important carbapenemases produced by Enterobacteriaceae are the class B61
metallo-β-lactamases (MBLs), represented by VIM, IMP and NDM types; the class A 62
enzymes of the KPC type; and the class D enzymes, represented by the OXA-48-type63
(3). In Spain, the number of reports on carbapenemase-producing Enterobacteriaceae64
(CPE) has increased in recent years (4-10). However comprehensive assessment of the65
impact of CPE in Spain is still missing.66
Our Institute runs an active and unrestricted Antibiotic Resistance Surveillance67
Program at the national level since 2009. When this program was launched, all Spanish68
clinical microbiology laboratories and health-associated professionals were personally69
contacted and encouraged to submit their carbapenem-resistant Enterobacteriaceae to70
our antibiotic reference lab for molecular and epidemiological characterization.71
Enterobacteriacea isolates were identified by standard microbiological methods72
and MicroScan semiautomated system (MicroScan, Siemens Healthcare Diagnostics,73
Deerfield, IL, USA). If necessary, species identification was confirmed by 16S74
ribosomal DNA sequencing.75
Antibiotic susceptibility testing was carried out by broth microdilution (Panel76
type Neg MIC 31, MicroScan) and by the disc diffusion method according to the77
EUCAST guidelines (11). Isolates were considered as non-susceptible to carbapenems78
if they were either resistant or intermediate to at least one of the three carbapenem79
antibiotics tested (imipenem, meropenem, and ertapenem) according to EUCAST80
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breakpoints (11). A modified Hodge test using an ertapenem disk was performed on all81
isolates. Inhibition of carbapenemase activity was carried out by comparing the82
inhibition zones obtained from ertapenem disks, with or without EDTA (10 μL 0.5 M 83
solution) and phenyl-boronic acid (400 µg).84
The presence of genes encoding carbapenemases blaKPC, blaVIM, blaIMP, and85
blaNDM was confirmed by PCR and DNA sequencing (5,12,13). Specific primers for86
PCR amplification and sequencing of blaOXA-48 like genes were designed according to87
GenBank (National Center for Biotechnology Information, National Institutes of Health,88
Bethesda, MD, USA) database entry AY236073 (OXA-48-TOT-F 5’ -89
TGCGTGTATTAGCCTTATCG- 3’; OXA-48-TOT-R: 5’ -90
TTTTTCCTGTTTGAGCACTTC- 3’).91
Multi-locus sequence type (MLST) was determined in all carbapenemase-92
producing K. pneumoniae according to the Institut Pasteur scheme93
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html; May 2013,94
data last accessed). E. coli isolates were typed by MLST according to the University95
College Cork (Cork, Ireland) scheme (http://mlst.ucc.ie/mlst/dbs/Ecoli; May 2013, data96
last accessed).97
During 2012, 357 isolates of Enterobacteriaceae non-susceptible to98
carbapenems were studied in detail, only one isolate per patient was considered. They99
came from 49 Spanish hospitals (about 20% of all Spanish microbiology laboratories)100
located in 24 geographic areas. The estimated catchment population was about 21.5%,101
corresponding to approximately 10.5 millions. Of these 357 isolates, 237 (66.4%) had a102
carbapenemase gene positively identified and distributed as follows: 203 (74.4%)103
carbapenemases identified in 273 carbapenems non-susceptible K. pneumoniae isolates;104
6 (75%) in 8 Klebsiella oxytoca; 16 (36.4%) in 44 Enterobacter cloacae; 2 (25%) in 8105
6
Enterobacter aerogenes; 4 (22.2%) in 18 Escherichia coli; and 6 (100%) in 6 single106
isolates of Serratia marcescens, Morganella morganii, Citrobacter freundii and107
Enterobacter spp (Table 1).108
One hundred and forty-nine (62.9%) isolates were from males and 76 (32.1%)109
from patients ≥ 65 years old. Of the 237 CPE, 162 (68.4%) produced clinical infections: 110
71 (43.8%) urinary tract infections (UTI), 37 (22.8%) blood infections, 28 (17.3%)111
respiratory tract infections, 13 (8%) wound infections, and 13 (8%) other infections.112
The remaining 75 isolates (31.6%) were obtained from carriers, mainly from rectal113
samples.114
The carbapenemases detected were: 163 OXA-48 group (84 OXA-48 and 79115
OXA-245), 60 VIM-1, 8 KPC-2, 5 IMP group (2 IMP-22 and 3 IMP-8), and one NDM-116
1 (Table 1). These CPE came from 30 Spanish hospitals (average of 8.1 CPE per117
hospital, range 1-83) located in 14 geographic areas. Six hospitals had more than 10118
CPE cases; the remaining 24 hospitals had between one and nine cases.119
Susceptibility to carbapenem antibiotics is depicted in Table 2; all120
carbapenemase-producing isolates were ertapenem non-susceptible, but of the OXA-48121
like and VIM-1 producers, 66.3% and 15% were susceptible to imipenem, respectively.122
From 2009 to 2012, we observed an increase in the number of CPE isolates123
submitted to the surveillance program: 15 isolates in 2009, 38 in 2010, 112 in 2011 and124
237 in 2012 (sixteen-fold increase). The number of hospital submitting cases increased125
from 6 in 2009 to 30 in 2012 (five-fold increase) (Figure 1). Although VIM-1 was the126
first carbapenemase described in Spain (14), its frequency has been widely surpassed by127
the abrupt emergence of OXA-48 in the last two years (Figure 1).128
The frequency and distribution of carbapenemases are distinct in different129
countries. A rapid dissemination of KPC-producing K. pneumoniae was first noticed in130
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the United States (3). Later, isolates producing KPC-2 and KPC-3 also emerged in Latin131
America, Israel and Greece (1,3). A recent study showed that KPC enzymes were the132
most common (89.5%) found in Italy (15). Outbreaks caused by OXA-48-producing K.133
pneumoniae have been described in several countries (1,3,16).134
According to our data, OXA-48 is by far the most common carbapenemase type135
circulating in Spain in K. pneumoniae (75.4% in this study), followed by VIM (19.7%).136
(Table 1). The carbapenemase-producing K. pneumoniae belonged to 12 different137
sequence types (STs) (Table 3), although most of them (88.7%) were carried by four138
major clones: ST11, ST15, ST16 and ST405. ST11, ST15, and ST16 have been139
described previously associated to different outbreaks due to ESBLs or carbapenemase-140
producing K. pneumoniae (1,7,9,17). ST405 was recently associated with OXA-48141
production in Spain and Belgium (7,8,16), and was found in this study in eight hospitals142
from three geographic regions. These data may suggest that ST405 has been established143
in Spain and contributes to the dissemination of OXA-48.144
The most common ST/carbapenemase associations found are detailed in Table 3.145
Only two STs carried more than one type of carbapenemase: ST11 (OXA-48, OXA-146
245, VIM-1, KPC-2 and NDM-1) and ST15 (VIM-1 and OXA-48). It should be147
emphasised the apparent capacity of ST11 to carry and disseminate different types of148
carbapenemases (1,7,17).149
The four carbapenemases-producing E. coli belonged to four different STs:150
ST10, ST226 and ST1152 with one case each of VIM-1, and ST131 that produced151
OXA-48.152
Our results are based on a large representative sample of Spanish CPE cases, but153
reporting of CPE is not mandatory in this country so far. Recent global data about the154
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spread of CPE in Spain are not available; one multicenter study carried out in 2009 in155
Spain detected only 43 CPE, mainly VIM-1 and IMP-22 (5).156
Only 13.5% of the isolates producing carbapenemases in this study were K.157
pneumoniae or E. coli isolated from blood suggesting that EARS-Net158
(http://www.ecdc.europa.eu/en/activities/surveillance/EARS-159
Net/database/Pages/database.aspx) may underestimate the occurrence of carbapenem-160
resistant Enterobacteriaceae. From 2011 to 2012, imipenem-non susceptible K.161
pneumonia has increase from <1% to 1.7% according to Spanish EARS-Net databases162
(unpublished data); similarly, according to Surveillance Program data depicted in Figure163
1, the number of carbapenemase-producing Enterobacteriaceae more than doubled164
between 2011 and 2012.165
It is remarkable that, from 2009 to 2012, the number of hospitals reporting CPE166
increased five times. This fact that may suggest that a recent epidemiological change167
may have occurred in this country, characterised by a rapid increase in the number of168
cases of CPE causing both nosocomial outbreaks and single infections (Table 3). A169
second significant factor explaining this trend may be that hospitals have increased170
awareness of CPE.171
In summary, our data suggest that the impact of CPE in Spain has dramatically172
increased in the last years. Inter-hospital spread of several K. pneumoniae173
clone/carbapenemase combinations have been detected in this study, mainly174
ST15/VIM-1, ST11/OXA-48, ST405/OXA-48, ST101/KPC-2 and ST11/VIM-1. To175
address the emergence and spread of CPE, urgent measures are required, including early176
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Table 1. Distribution of carbapenemase-producing Enterobacteriaceae in 2012 in Spain266















K. pneumoniae 203 (85.6) 153 40 6 3 1
K. oxytoca 6 (2.5) 0 6 0 0 0
E. cloacae 16 (6.8) 7 6 1 2 0
E. aerogenes 2 (0.8)
4 (1.7)
2 0 0 0 0
E. coli 1 3 0 0 0
S. marcescens 1 (0.4) 0 0 1 0 0
M. morgannii 1 (0.4) 0 1 0 0 0
C. freundii 1 (0.4) 0 1 0 0 0
Enterobacter spp. 3 (1.3) 0 3 0 0 0





Table 2. Susceptibilty to carbapenem antibiotics in carbapenemase-producing273
Enterobacteriaceae isolated in Spain (2012).274
275
Carbapenemase type Carbapenem Rangea MIC50
a MIC90
a %S %I %R
OXA-48 like
(n=163)
Ertapenem 2->4 4 >4 0 0 100
Imipenem ≤1->8 2 >8 66.3 20.2 13.5
Meropenem ≤1->8 4 >8 30 47.9 22.1
VIM-1
(n=60)
Ertapenem 1->4 4 >4 0 10 90
Imipenem ≤1->8 4 >8 15 55 30
Meropenem ≤1->8 8 >8 18.3 40 41.7
IMP-like
(n=5)
Ertapenem 4->4 >4 >4 0 0 100
Imipenem ≤1-2 2 2 100 0 0
Meropenem 2->8 8 >8 20 60 20
KPC-like
(n=8)
Ertapenem >4->4 >4 >4 0 0 100
Imipenem 4->8 4 >8 0 75 25
Meropenem 2->8 8 >8 25 25 50
276
a Expressed in µg/mL.277
%S: Percentage of susceptible isolates according to EUCAST breakpoints.278
%I: Percentage of intermediate isolates according to EUCAST breakpoints.279
%R: Percentage of resistant isolates according to EUCAST breakpoints.280
281
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Figure 1. Yearly evolution (2009-2012) of carbapenemase-producing282
Enterobacteriaceae in Spain and number of individual hospitals reporting cases to the283


































Table 3. Distribution of Klebsiella pneumoniae MLST clones producing291
carbapenemases in Spain in 2012 according to the national surveillance program of the292
Instituto de Salud Carlos III.293
294





11 OXA-245 76 1 Málaga
VIM-1 14 6 Madrid, Guadalajara
OXA-48 12 7 Madrid
KPC-2 3 3 Madrid, Ciudad Real
NDM-1 1 1 Alicante
15 VIM-1 15 4 Madrid, Barcelona, Ávila
OXA-48 4 2 Madrid, Málaga
405 OXA-48 38 8 Madrid, Barcelona, Guadalajara
16 OXA-48 17 2 Asturias
147 VIM-1 5 1 Alicante
340 VIM-1 5 1 Madrid
437 OXA-245 3 1 Málaga
101 KPC-2 3 2 Madrid
464 IMP-8 3 1 Almeria
846 OXA-48 2 1 Madrid
13 OXA-48 1 1 Barcelona
1235 VIM-1 1 1 Guadalajara
295
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